Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tecalcet. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR known ✓ | P41180 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | HRH2 | P25021 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | HTR5A | P47898 | 1/20 | 0.98 |
| ▸ | HTR6 | P50406 | 1/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.98 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tecalcet SCHEMBL1275509 | 1.00 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL30092843 | 1.00 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL31424074 | 1.00 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL31424064 | 1.00 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL896469 | 1.00 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL29374613 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL1178449 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL1178446 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| SCHEMBL6222202 | 0.96 | CASR (0.93) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| SCHEMBL7355756 | 0.92 | CASR (0.84) | CASRHTR1AADRA2BADRA2CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | SANIFIT THERAPEUTICS S A (ES) | 2026-04-16 | — | — | US | claimed |
| US-20250295676-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | VIFOR (INTERNATIONAL) LTD. (CH) | 2025-09-25 | — | — | US | claimed |
| US-20220249521-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | Sanifit Therapeutics S.A. (ES) | 2022-08-11 | — | — | US | claimed |
| US-20190134054-A1 | ASSOCIATION OF ANTAGONISTS OF THE VASOPRESSIN RECEPTOR AND CALCIMIMETICS, COMPOSITION AND USE THEREOF FOR THE TREATMENT OF POLYCYSTIC KIDNEY | UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO (IT) | 2019-05-09 | — | — | US | claimed |
| EP-3427753-A1 | COMBINATION OF ANTAGONISTS OF THE VASOPRESSIN RECEPTOR AND CALCIOMIMETICS, COMPOSITION AND USE THEREOF FOR THE TREATMENT OF POLYCYSTIC KIDNEY | Università degli Studi di Bari "Aldo Moro" (IT) | 2019-01-16 | — | — | EP | claimed |
| US-10010559-B2 | Use of derivatives containing C-O-P bonds in patients with kidney failure | LABORATORIOS SANIFIT, S.L. (ES) | 2018-07-03 | — | — | US | claimed |
| US-20170020903-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | VIFOR (INTERNATIONAL) LTD. (CH) | 2017-01-26 | — | — | US | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070060625-A1 | Methods of modulating intestinal fluid balance | AMGEN INC. (US) | 2007-03-15 | — | — | US | claimed |
| WO-2007027548-A2 | METHODS OF MODULATING INTESTINAL FLUID BALANCE | AMGEN INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-20060276534-A1 | Methods of decreasing calcification | AMGEN INC. (US) | 2006-12-07 | — | — | US | claimed |
| EP-1281702-A2 | Calcium receptor active molecules | NPS PHARMACEUTICALS, INC. (US) | 2003-02-05 | — | — | EP | claimed |
| US-6313146-B1 | CAN BE USED FOR THERAPY OF DISEASES OR DISORDERS IN A PATIENT BY MODULATING ONE OR MORE INORGANIC ION RECEPTOR ACTIVITIES | NPS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | claimed |
| US-6031003-A | TREATING A PATIENT HAVING A DISEASE OR DISORDER TREATABLE BY MODULATING ACTIVITY OF CALCIUM RECEPTORS IN VITRO BY ADMINISTERING A CALCIMIMETIC COMPOUND DETERMINED BY THE CALCILYTIC BOVINE PARATHYROID CELL TEST; OSTEOPOROSIS | NPS PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | claimed |
| US-5504253-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1996-04-02 | — | — | US | claimed |
| WO-1996002492-A1 | METHOD OF MAKING A BENZYLPROPANAMINE | NSP PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020903-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | ATP6V1B1, PROC, GC | CASR 49/4885HTR1A 4771/4885ADRA2B 1630/4885 |
| US-20250295676-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | PPIP5K2, INPP5B, IP6K3 | CASR 46/4885HTR1A 4363/4885ADRA2B 3608/4885 |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | CASR 1710/4885HTR1A 1381/4885ADRA2B 2797/4885 |
| US-20220249521-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | ATP6V1B1, PROC, GC | CASR 43/4885HTR1A 4777/4885ADRA2B 1684/4885 |
| US-20060276534-A1 | Methods of decreasing calcification | CALCB, CALCA, CALCR | CASR 9/4885HTR1A 4131/4885ADRA2B 1371/4885 |
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | ATP6V1B1, IP6K3, IP6K1 | CASR 28/4885HTR1A 4192/4885ADRA2B 1581/4885 |
| US-10010559-B2 | Use of derivatives containing C-O-P bonds in patients with kidney failure | ATP6V1B1, PROC, GC | CASR 43/4885HTR1A 4777/4885ADRA2B 1684/4885 |
| US-20070060625-A1 | Methods of modulating intestinal fluid balance | SLC10A2, VIP, FABP2 | CASR 23/4885HTR1A 2979/4885ADRA2B 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.